Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1693
This examiner grants 38% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17768922 | METHODS OF TREATING CANCER WITH A STING AGONIST | Final Rejection | The Board of Regents of the University of Texas System |
| 17705762 | DEPOLYMERIZATION AND VALORIZATION OF A BIOPOLYMER | Non-Final OA | NEW YORK UNIVERSITY |
| 18088628 | COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID | Final Rejection | Industrial Technology Research Institute |
| 17906560 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | Battelle Memorial Institute |
| 18061323 | HEPARANASE INHIBITORS FOR TREATMENT OF DIABETES | Final Rejection | Wayne State University |
| 18176864 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Gilead Sciences, Inc. |
| 18554318 | A METHYLCELLULOSE WITH HIGH POWDER DISSOLUTION TEMPERATURE | Non-Final OA | Nutrition & Biosciences USA 1, LLC |
| 18548997 | ANTIVIRAL AGENT | Final Rejection | TOYOBO CO., LTD. |
| 18249245 | IMPROVED SOPHOROLIPID DERIVATIVES WITH THERAPEUTIC AGENT CARGOS AND THEIR USE | Non-Final OA | LOCUS SOLUTIONS IPCO, LLC |
| 18553144 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | Non-Final OA | Chimerix, Inc. |
| 17636536 | NEW USE OF CYCLIC DINUCLEOTIDES | Final Rejection | Helmholtz-Zentrum für Infektionsforschung GmbH |
| 18484111 | METHODS FOR THE TREATMENT OF PROTEINOPATHIES | Non-Final OA | RENATUS INC. |
| 18554442 | A COMPOSITION FOR IMPROVING GUT MICROBIOTA, BEHAVIOURAL PATTERN, ALPHA-SYNUCLEIN LEVELS, SLEEP PATTERN AND/OR SERUM MELATONIN | Non-Final OA | Sophy Inc. |
| 18476600 | METHODS AND COMPOSITIONS FOR TREATING CLOSTRIDIODES DIFFICILE INFECTIONS | Non-Final OA | Matrivax, Inc. |
| 18549010 | AGENT FOR ENHANCING HAIR-SETTING ABILITY | Non-Final OA | Hayashibara Co., Ltd. |
| 17758495 | Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment | Non-Final OA | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
| 18283478 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | Non-Final OA | HK INNO.N CORPORATION |
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Non-Final OA | NeuroDerm, Ltd. |
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | Non-Final OA | Idorsia Pharmaceuticals Ltd |
| 18458250 | DEOXYNUCLEOSIDE MODIFIED RUTHENIUM COMPLEX, AND PREPARATION METHOD AND USE THEREOF | Non-Final OA | Guangzhou Ruby Biotechnology Co., Ltd. |
| 18267867 | DEXTRIN WITH IMPROVED TURBIDITY, AND METHOD FOR PRODUCING SAME | Non-Final OA | SAMYANG CORPORATION |
| 17998942 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | Final Rejection | GLYCOMIMETICS, INC. |
| 18264879 | METHODS FOR PREVENTING CANCER RELAPSE | Non-Final OA | Department of Veterans Affairs |
| 17790697 | ALKYLATED NUCLEOSIDES, AND COMPOSITIONS AND METHODS THEREOF FOR NUCLEIC ACID DELIVERY | Final Rejection | MICROVASCULAR THERAPEUTICS, LLC |
| 18019404 | SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES | Non-Final OA | Dicerna Pharmaceuticals, Inc. |
| 18007407 | NOVEL THERAPEUTIC USES OF COMPOUNDS FOR ENHANCING MITOCHONDRIAL FUNCTION AND TREATING MITOCHONDRIAL DISEASES | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18300468 | PHARMACOLOGIC APPROACH FOR SUPPRESSION OF CORONAVIRUSES | Final Rejection | Temple University - of the Commonwealth System of Higher Education |
| 18029062 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | Beijing Creatron Institute of Pharmaceutical Research Co. Ltd. |
| 18043518 | FORMULATIONS OF ANTI-VIRAL COMPOUNDS | Non-Final OA | Sayvaa Pharmaceuticals Inc. |
| 18020880 | FORMULATIONS OF NICOTINIC ACID DERIVATIVES AND FLAVONOID POLYPHENOLS AND USES THEREOF | Final Rejection | Animal Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy